Morgan Stanley
RVMD icon

Morgan Stanley’s Revolution Medicines RVMD Stock Holding History

Morgan Stanley’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$157M Buy
838,249
+132,456
+19% +$19.3M 0.01% 1205
2026
Q1 		$68.6M Buy
705,793
+54,061
+8% +$5.46M ﹤0.01% 1785
2025
Q4 		$51.9M Sell
651,732
-782,910
-55% -$51.3M ﹤0.01% 2045
2025
Q3 		$67M Buy
1,434,642
+383,605
+36% +$15M ﹤0.01% 1760
2025
Q2 		$38.7M Sell
1,051,037
-204,650
-16% -$7.86M ﹤0.01% 2158
2025
Q1 		$44.4M Buy
1,255,687
+397,409
+46% +$16.1M ﹤0.01% 1919
2024
Q4 		$37.5M Buy
858,278
+205,460
+31% +$10.4M ﹤0.01% 2102
2024
Q3 		$29.6M Sell
652,818
-342,671
-34% -$14.9M ﹤0.01% 2395
2024
Q2 		$38.6M Buy
995,489
+68,419
+7% +$2.56M ﹤0.01% 1987
2024
Q1 		$29.9M Sell
927,070
-726,104
-44% -$21.5M ﹤0.01% 2251
2023
Q4 		$47.4M Buy
1,653,174
+851,201
+106% +$20.5M ﹤0.01% 1784
2023
Q3 		$22.2M Sell
801,973
-181,522
-18% -$5.38M ﹤0.01% 2338
2023
Q2 		$26.3M Buy
983,495
+598,758
+156% +$14.7M ﹤0.01% 2189
2023
Q1 		$8.33M Buy
384,737
+46,761
+14% +$1.15M ﹤0.01% 3313
2022
Q4 		$8.05M Buy
337,976
+86,212
+34% +$1.83M ﹤0.01% 3284
2022
Q3 		$4.96M Buy
251,764
+9,734
+4% +$214K ﹤0.01% 3702
2022
Q2 		$4.72M Buy
242,030
+54,261
+29% +$1.06M ﹤0.01% 3823
2022
Q1 		$4.79M Buy
187,769
+138,843
+284% +$3.02M ﹤0.01% 3738
2021
Q4 		$1.23M Sell
48,926
-51,057
-51% -$1.44M ﹤0.01% 4922
2021
Q3 		$2.75M Sell
99,983
-426,435
-81% -$12.4M ﹤0.01% 4306
2021
Q2 		$16.7M Buy
526,418
+367,073
+230% +$12.8M ﹤0.01% 2360
2021
Q1 		$7.31M Buy
159,345
+129,118
+427% +$5.79M ﹤0.01% 3000
2020
Q4 		$1.2M Sell
30,227
-21,957
-42% -$868K ﹤0.01% 4562
2020
Q3 		$1.82M Buy
52,184
+22,431
+75% +$621K ﹤0.01% 3743
2020
Q2 		$939K Sell
29,753
-17,751
-37% -$558K ﹤0.01% 4228
2020
Q1 		$1.04M Buy
+47,504
New +$1.32M ﹤0.01% 3918

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley's RVMD Position: Q2 2026 in Review

Morgan Stanley increased its Revolution Medicines (RVMD) stake by 19% in Q2 2026, buying an estimated $19.3M and bringing the position to 838,249 shares worth $157M. The position accounts for 0.01% of the portfolio, ranked #1205.

Morgan Stanley first reported a position in RVMD in Q1 2020 and has held it in 26 quarters since. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Morgan Stanley held 838,249 shares of Revolution Medicines worth $157M as of Q2 2026.
  • Morgan Stanley bought 132,456 Revolution Medicines shares in Q2 2026, an estimated $19.3M.
  • Revolution Medicines made up 0.01% of Morgan Stanley's portfolio in Q2 2026, its #1205 holding.
  • Morgan Stanley first reported a position in Revolution Medicines in Q1 2020 and has held it in 26 quarters since.
  • 690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.